PubMed Health⌕ Search

PubMed · 11669870

Osmium Hydrazido and Dinitrogen Complexes.

Abstract

[Os(tpy)(bpy)(NH(3))](PF(6))(2) (1) was oxidized electrochemically in the presence of a series of amines in aqueous solutions buffered to pH 7. With secondary aliphatic amines, electrolysis gave [Os(tpy)(bpy)(NNR(2))](PF(6))(3) (3); number of electrons n = 4.6-5.0. 3 was reduced to [Os(tpy)(bpy)(NNR(2))](PF(6))(2) (2) in aqueous and nonaqueous solutions with n = 1.0. The structures of 2 were determined by X-ray crystallography for NR(2) = diethylamide (2a) and morpholide (2c) and were found to exhibit bent hydrazido(2-) coordination (Os-N-N = 137 degrees ). The salts crystallized in the triclinic system, space group P&onemacr;. For 2a, a = 9.004(1) Å, b = 9.796(1) Å, c = 20.710(2) Å, alpha = 88.78(2) degrees, beta = 85.43(2) degrees, gamma = 86.22(2) degrees, and Z = 2. For 2c, a = 9.632(8) Å, b = 21.229(9) Å, c = 9.039(5) Å, alpha = 97.41(4) degrees, beta = 94.28(5) degrees, gamma = 85.07(5) degrees, and Z = 2. Solutions of 2 were protonated in strongly acidic media to give hydrazido(1-) complexes. The pK(a) of the protonated form of 2a is 0.90 +/- 0.01. Reduction of 2 in aqueous solutions of pH <1 gave 1 and NH(2)R(2)(+) with n = 4.0. At higher pH, there is evidence for an Os(II) hydrazine intermediate. Oxidation of 3 by one electron afforded transiently stable species which decomposed to give [Os(tpy)(bpy)(NCCH(3))](3+) in acetonitrile solution. Pseudo-first-order rate constants of 8.1 +/- 0.9 s(-)(1) and 0.200 +/-.005 s(-)(1) were estimated by cyclic voltammetry on solutions of 2a and 2b(NR(2) = piperidide), respectively. Oxidation of 1 at pH 7, in the presence of primary aliphatic amines or ammonia, occurred with n = 5.9-6.2, and generated [Os(II)(tpy)(bpy)(N(2))](PF(6))(2) (4).

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

George M. Coia, Martin Devenney, Peter S. White, Thomas J. Meyer, David A. Wink. 1997-05-21. Osmium Hydrazido and Dinitrogen Complexes.. https://doi.org/10.1021/ic961025v

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗